Geode Capital Management
PRLD icon

Geode Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Geode Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.49M Buy
841,862
+539,404
+178% +$2.35M ﹤0.01% 2972
2026
Q1 		$1.03M Buy
302,458
+29,572
+11% +$77.5K ﹤0.01% 3345
2025
Q4 		$792K Buy
272,886
+55,318
+25% +$93.3K ﹤0.01% 3446
2025
Q3 		$313K Hold
217,568
– – ﹤0.01% 3782
2025
Q2 		$176K Sell
217,568
-187,387
-46% -$162K ﹤0.01% 3914
2025
Q1 		$311K Buy
404,955
+2,619
+0.7% +$2.44K ﹤0.01% 3708
2024
Q4 		$513K Buy
402,336
+10,620
+3% +$14.1K ﹤0.01% 3584
2024
Q3 		$811K Buy
391,716
+29,765
+8% +$138K ﹤0.01% 3427
2024
Q2 		$1.38M Buy
361,951
+319
+0.1% +$1.3K ﹤0.01% 3202
2024
Q1 		$1.71M Buy
361,632
+12,265
+4% +$47.7K ﹤0.01% 3175
2023
Q4 		$1.49M Buy
349,367
+18,267
+6% +$55.6K ﹤0.01% 3194
2023
Q3 		$1.02M Buy
331,100
+88,806
+37% +$333K ﹤0.01% 3307
2023
Q2 		$1.09M Buy
242,294
+96,390
+66% +$576K ﹤0.01% 3317
2023
Q1 		$832K Buy
145,904
+1,227
+0.8% +$7.48K ﹤0.01% 3427
2022
Q4 		$873K Sell
144,677
-8,414
-5% -$53.9K ﹤0.01% 3408
2022
Q3 		$1.01M Buy
153,091
+17,450
+13% +$118K ﹤0.01% 3380
2022
Q2 		$708K Sell
135,641
-71,935
-35% -$366K ﹤0.01% 3571
2022
Q1 		$1.43M Sell
207,576
-5,060
-2% -$46.3K ﹤0.01% 3434
2021
Q4 		$2.65M Sell
212,636
-36,536
-15% -$594K ﹤0.01% 3236
2021
Q3 		$7.79M Buy
249,172
+25,920
+12% +$839K ﹤0.01% 2646
2021
Q2 		$6.39M Buy
223,252
+24,061
+12% +$857K ﹤0.01% 2755
2021
Q1 		$8.63M Buy
199,191
+7,563
+4% +$502K ﹤0.01% 2453
2020
Q4 		$13.7M Buy
+191,628
New +$9.53M ﹤0.01% 1948

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Geode Capital Management's PRLD Position: Q2 2026 in Review

Geode Capital Management increased its Prelude Therapeutics (PRLD) stake by 178% in Q2 2026, buying an estimated $2.35M and bringing the position to 841,862 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Geode Capital Management first reported a position in PRLD in Q4 2020 and has held it in 23 quarters since. The position peaked at $13.7M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Geode Capital Management held 841,862 shares of Prelude Therapeutics worth $4.49M as of Q2 2026.
  • Geode Capital Management bought 539,404 Prelude Therapeutics shares in Q2 2026, an estimated $2.35M.
  • Prelude Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2972 holding.
  • Geode Capital Management first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's Prelude Therapeutics position peaked at $13.7M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.